AbCellera Biologics Inc. (ABCL) Earnings History
Annual and quarterly earnings data from 2018 to 2025
Loading earnings history...
ABCL EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
ABCL Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 0.0% | -289.0% | -194.9% |
| 2024 | 100.0% | -1091.7% | -564.8% |
| 2023 | 100.0% | -623.8% | -385.0% |
| 2022 | 86.3% | 44.6% | 32.7% |
| 2021 | 87.9% | 54.5% | 40.9% |
Download Data
Export ABCL earnings history in CSV or JSON format
Free sign-in required to download data
AbCellera Biologics Inc. (ABCL) Earnings Overview
As of May 8, 2026, AbCellera Biologics Inc. (ABCL) reported trailing twelve-month net income of -$146M, reflecting +10.9% year-over-year growth. The company earned $-0.49 per diluted share over the past four quarters, with a net profit margin of -194.9%.
Looking at the long-term picture, ABCL's historical earnings data spans multiple years. The company achieved its highest annual net income of $159M in fiscal 2022.
AbCellera Biologics Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including TWST (-$81M net income, -20.6% margin), RXRX (-$560M net income, -863.4% margin), SDGR (-$103M net income, -40.4% margin), ABCL has room to improve margins relative to the peer group. Compare ABCL vs TWST →
ABCL Earnings vs Peers
Earnings metrics vs comparable public companies
ABCL Historical Earnings Data (2018–2025)
8 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$146M | +10.1% | -$217M | $-0.49 | -194.9% | -289.0% |
| 2024 | -$163M | -11.2% | -$315M | $-0.55 | -564.8% | -1091.7% |
| 2023 | -$146M | -192.4% | -$237M | $-0.51 | -385.0% | -623.8% |
| 2022 | $159M | +3.3% | $217M | $0.50 | 32.7% | 44.6% |
| 2021 | $153M | +29.1% | $204M | $0.48 | 40.9% | 54.5% |
| 2020 | $119M | +5478.5% | $156M | $0.45 | 51.0% | 66.9% |
| 2019 | -$2M | -815.5% | -$4M | $-0.01 | -19.0% | -35.5% |
| 2018 | $309,000 | - | $-753,000 | $0.00 | 3.5% | -8.5% |
See ABCL's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ABCL Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ABCL vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonABCL — Frequently Asked Questions
Quick answers to the most common questions about buying ABCL stock.
Is ABCL growing earnings?
ABCL EPS stands at $-0.49, with +10.9% growth matching the 5-year CAGR of N/A. TTM net income is $-146M. Earnings trajectory remains consistent.
What are ABCL's profit margins?
AbCellera Biologics Inc. net margin is -194.9%, with operating margin at -289.0%. Below-average margins reflect competitive or cost pressures.
How consistent are ABCL's earnings?
ABCL earnings data spans 2018-2025. The current earnings trend is +10.9% YoY. Historical data enables comparison across business cycles.